Skip to main content

Advertisement

Table 2 Clinical characteristics of the patients in the CERTIM NSCLC cohort

From: The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Characteristic Category N (%)
Sex M 23 (62%)
F 14 (38%)
Age (year) Median (range) 68 (41–78)
Tumor type Adenocarcinoma 25 (68%)
Squamous cell carcinoma 10 (27%)
NOS 2 (5%)
Smoking status Non smoker 4 (11%)
Smokers 33 (88%)
 < 10 pack/year (≤ 10 packs years)
 [10–30] pack/year 19 (57%)
 > 30 pack/year 14 (42%)
 Quit > 1 year 19 (57%)
 Active or quit ≤ 1 year 14 (42%)
ECOG performance status 0 1 (3%)
1 18 (49%)
≥ 2 18 (49%)
Previous lines of therapy 0
1 22 (59%)
2 6 (16%)
≥ 3 9 (24%)
ORR CR 3 (8%)
PR 4 (11%)
SD 6 (16%)
PD 24 (65%)